

Adamas Pharmaceuticals Inc

COMPANY AND PIPELINE OVERVIEW REPORT

A comprehensive coverage of the company and a summary of the drug pipeline portfolio.

Publication Date: 26-Apr-2015

THOMSON REUTERS

3 Times Square
New York, New York 10036
United States

Tel: +1 646 223 4000

thomsonreuters.com

[Return to Table of Contents](#)



ABOUT COMPANY AND PIPELINE OVERVIEW REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

Cortellis Company and Pipeline Overview reports are the first in a series of reports that track pharmaceutical and biotechnology companies worldwide. Further report offerings planned to follow include: Company Detailed Pipeline and Company Competitive Landscape reports. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from a significant number of global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence*

DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



GLOSSARY

Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



PLEASE NOTE: the financials section where present in the report includes: Share Information, Stock Performance chart (including the consensus recommendation), and Major Shareholders. Financial Performance presents graphical and tabular data on Worldwide Sales, Operating Income and Net Income over time, together with a Quarterly earnings update. Balance Sheet lists Assets, Liabilities and Stockholders Equity, and Forecasts includes: EPS Forecast and Other Forecasts. The data reported in all sections (except share information and major stock holders) are correct as of the publication date of the report (and not the download date). For share information and major stock holders the data is correct for the date shown with these sections

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 7

Company Profile..... 7

Company Financials..... 7

Product Portfolio Summary..... 11

Product Portfolio Drugs..... 15

[Return to Table of Contents](#)

Adamas Pharmaceuticals Inc

COMPANY OVERVIEW

Company Name	Adamas Pharmaceuticals Inc
Parent Company Name	Adamas Pharmaceuticals Inc
Website	http://adamaspharma.com/
Country	US
Number of Drugs in Active Development	3
Number of Inactive Drugs	8
Number of Patents as Owner	18
Number of Patents as Third Party	2
Number of Deals	5
Key Indications	Fatigue, Movement disorder, Parkinsons disease, Alzheimers disease, Traumatic brain injury, Unidentified indication, Brain injury, Neurological disease, Sleep disorder, Glaucoma, HIV associated dementia, Hepatitis C virus infection, Neuropathic pain, Respiratory syncytial virus infection
Key Target-based Actions	NMDA receptor antagonist, Inosine monophosphate dehydrogenase inhibitor, Influenza matrix protein 2 inhibitor, Acetylcholinesterase inhibitor, Exo-alpha sialidase inhibitor, Folate antagonist, Nitric oxide synthase inhibitor
Key Technologies	Small molecule therapeutic, Drug combination, Oral formulation, Capsule formulation, Sustained release formulation, Oral sustained release formulation, Intravenous formulation, Systemic formulation unspecified, Quick release formulation, Controlled release formulation, Formulation preservation, Tablet formulation

COMPANY PROFILE

SUMMARY

Adamas Pharmaceuticals (formerly NeuroMolecular Pharmaceuticals Inc), headquartered in Emeryville, CA, was founded in 2004 and is focused on the development of controlled release, novel small molecule therapeutics called advantaged therapeutics for neurological like Alzheimer's diseases and dementia and infectious diseases like influenza.

FINANCIAL

In April 2014, Adamas priced its IPO of 3 million common stock shares at \$16 each. The underwriters were granted a 30-day over-allotment option to purchase up to an additional 450,000 common stock shares. At that time, shares were expected to begin trading on the NASDAQ Global Market under the ticker symbol 'ADMS' on April 10, 2014 and the offering was expected to close on April 15, 2014; later that month, the offering was closed and net proceeds from the offering was estimated to be approximately \$41.5 million; later that month, the company issued 81,371 additional shares to the underwriters pursuant to the over-allotment option and raised net proceeds of approximately \$42.7 million. And the shares had begun trading on NASDAQ.

In August 2009, the company raised \$40 million from a series D financing round.

COMPANY FINANCIALS

SHARE INFORMATION

Close Price (USD)	17.70
Change (USD)	-0.03 (-0.17%)

[Return to Table of Contents](#)



Previous Close Price (USD)	17.73
Volume	52,795
52-Week High (USD)	21.63
52-Week Low (USD)	13.60
Date	24-Apr-2015
Exchange	NASDAQ(COMPOSITE)
Current Number of Shares Outstanding	17,705,406
Current Market Capitalization	313,385,686
EPS (Date Reported)	0.59759

STOCK PERFORMANCE



MAJOR SHAREHOLDERS

Shareholder	Type	Country	Shares held	% of shares held	Change in holding	% changes in shares held	Date
Went (Gregory T)	Individual Investor	United States	613,788	3.47	10,000	0.02	21-Apr-2015

Lieberburg (Ivan M)	Individual Investor	United States	88,000	0.5	-3,000	-0.03	06-Apr-2015
Booth (Richard H)	Individual Investor	United States	47,778	0.27	-1,000	-0.02	15-Apr-2015
Mcclure (Natalie lewis)	Individual Investor	United States	840	0	0	0	06-Apr-2015

FINANCIAL PERFORMANCE



	2011	2012	2013	2014	
Sales (USD M)	1.982	37.471	71.095	55.846	
Operating Income (USD M)	-8.058	19.949	57.018	18.514	
Net Income (USD M)	-8.244	17.736	50.921	10.223	

[Return to Table of Contents](#)

Quarterly earnings update

Period	Sales (USD M)	Operating Income (USD M)	Net Income (USD M)
2014 Q4	30.301	17.036	9.731
2014 Q3	0.215	-9.55	-9.557
2014 Q2	25.154	16.719	16.429
2014 Q1	0.176	-5.691	-6.38
2013 Q4	40.11	35.124	30.944
2013 Q2	0.241	-2.694	-3.353
2012 Q4	36.351	29.222	28.286

BALANCE SHEET

Assets (USD M)

	2011	2012	2013	2014
Cash & Short Term Investments	3.117	62.957	85.612	122.358
Inventories - Total	0	0	0	0
Current Assets - Total	3.957	64.195	86.008	123.527
Property, Plant And Equipment - Net	0.117	0.099	0.199	1.228
Other Assets - Total	0.009	0.009	0.009	0.07
Total Assets	4.083	64.303	86.216	161.189

Liabilities (USD M)

	2011	2012	2013	2014
Accounts Payable	1.456	3.255	2.097	3.685
Short Term Debt & Current Portion Of Long Term Debt	0	4	0	0
Current Liabilities - Total	2.262	38.48	4.218	12.545
Long Term Debt	0	0	0	0
Other Liabilities	0.117	1.706	6.244	1.57
Total Liabilities	2.379	40.186	10.462	14.115

[Return to Table of Contents](#)



Stockholders Equity (USD M)

	2011	2012	2013	2014	
Minority Interest	0	0	0	0	
Preferred Stock	15.336	19.149	19.149	0	
Common Stock	0.014	0.014	0.014	0.022	
Treasury Stock	0	0	0	0	
Total Liabilities & Shareholders' Equity	4.083	64.303	86.216	161.189	

FORECASTS

EPS Forecast

Year ending	Current Forecast	1 month ago	3 months ago
31-Dec-2015	-3.1	-2.75	-0.93
31-Dec-2016	-3.24	-2.95	-2.71
31-Dec-2017	-2.02	-2	-1.63

Other Forecasts

Year ending	DPS	CPS	Pretax	Sales
31-Dec-2015	0	2.36	-43.16	6.85
31-Dec-2016	0	-3.85	-54.4	1.33
31-Dec-2017	0	-2.03	-34.77	30.25


[Return to Table of Contents](#)

PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart




Drugs by Indication Table

Indication	Active	Inactive	Total
Neurological disease	2	4	6
Infectious disease	0	3	3
Respiratory disease	0	2	2
Degeneration	1	1	2
Unidentified indication	1	1	2
Injury	1	0	1
Fatigue	1	0	1

[Return to Table of Contents](#)

Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

Development Status	Number of Drugs
Registered	1
Phase 3 Clinical	1
Discovery	1
Discontinued	1
No Development Reported	7

DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Drug - Funding	2	0	0	0	2
Drug - CRADA	1	0	0	0	1
Drug - Development/Commercialization License	1	0	0	0	1
Drug - Manufacturing/Supply	0	0	1	0	1

[Return to Table of Contents](#)

CLINICAL TRIALS

Trials by Condition Studied

Condition Studied	Ongoing	All
Neurological disease	3	5
Infectious disease	0	2
Respiratory disease	0	2

Trials by Phase

Phase	Ongoing	All
Phase 3	3	4
Phase 2	0	3
Phase 1	0	1

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

PATENTS *

Indication	As Owner	As Third Party	Total
Cardiovascular disease	1	0	1
Gastrointestinal disease	2	0	2
Growth disorder	1	0	1
Degeneration	5	0	5
Immune disorder	6	0	6
Psychiatric disorder	5	0	5
Musculoskeletal disease	1	0	1
Ocular disease	2	0	2
Genetic disorder	1	0	1
Metabolic disorder	1	0	1

[Return to Table of Contents](#)



Neurological disease	17	0	17
Respiratory disease	5	0	5
Infectious disease	5	0	5
Injury	2	0	2
Toxicity and intoxication	2	0	2
Inflammatory disease	2	0	2
Fatigue	1	0	1

* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)

PRODUCT PORTFOLIO DRUGS

PLEASE NOTE: Highest status refers to highest development of that drug for one of the active companies

memantine hydrochloride ER + donepezil hydrochloride (extended release formulation, dementia), Adamas/Actavis

Drug Name	memantine hydrochloride ER + donepezil hydrochloride (extended release formulation, dementia), Adamas/Actavis
Key Synonyms	Namzaric, Arimenda
Originator Company	Adamas Pharmaceuticals Inc
Active Companies	Adamas Pharmaceuticals Inc, Actavis plc
Inactive Companies	Forest Laboratories Inc
Highest Status	Registered
Active Indications	Alzheimers disease
Target-based Actions	NMDA receptor antagonist, Acetylcholinesterase inhibitor
Other Actions	Nootropic agent, Neuroprotectant
Technologies	Drug combination, Oral formulation, Capsule formulation, Oral sustained release formulation, Small molecule therapeutic
Last Change Date	23-Apr-2015

amantadine (extended release, Parkinson's disease/traumatic brain injury/fatigue), Adamas

Drug Name	amantadine (extended release, Parkinson's disease/traumatic brain injury/fatigue), Adamas
Key Synonyms	Nurelin, amantadine
Originator Company	Adamas Pharmaceuticals Inc
Active Companies	Adamas Pharmaceuticals Inc
Inactive Companies	
Highest Status	Phase 3 Clinical
Active Indications	Movement disorder, Fatigue, Traumatic brain injury
Target-based Actions	
Other Actions	Nootropic agent, Neuroprotectant, Antiparkinsonian
Technologies	Oral formulation, Capsule formulation, Sustained release formulation, Small molecule therapeutic
Last Change Date	10-Apr-2015

[Return to Table of Contents](#)



ADS-9000

Drug Name	ADS-9000
Key Synonyms	
Originator Company	Adamas Pharmaceuticals Inc
Active Companies	Adamas Pharmaceuticals Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Unidentified indication
Target-based Actions	
Other Actions	Unspecified drug target
Technologies	Small molecule therapeutic
Last Change Date	15-Dec-2014

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone.

For subscription information, e-mail scientific.lifesciences@thomsonreuters.com.

© 2012 Thomson Reuters. All rights reserved.
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

